Study reports spike in Covid-19 cases with dry, red, itchy eyes

59

New Delhi, March 6 (IANS) A team of Indian-origin researchers has found an increasing link between Covid infection and people presenting eye problems like dryness, redness and itchy eyes.

While Covid has primarily been a respiratory infection, the ocular system has shown susceptibility to the SARS-CoV-2 virus with numerous symptoms reported across the globe, said the team from Kiran C. Patel College of Osteopathic Medicine Nova Southeastern University,

Their study, published in the Cureus: Journal of Medical Science, identified conjunctivitis as the most common ocular symptom, with approximately one in every ten patients presenting the symptoms associated with Covid.

The team also reported more serious complications such as episcleritis — a benign, inflammatory disease that affects the clear tissue that covers the white part of your eyes, and is unrelated to Covid infection; Ophthalmoparesis — a weakness or paralysis of any of the extraocular muscles that garner movement of the eye; Central Retinal Artery Occlusion (CRAO) — a serious disease of the eye in which the main artery supplying the retina is blocked due to an atherosclerotic plaque.

Some Covid patients also reported suffering cranial nerve palsies, where an individual takes longer than usual to move eyes. It can also lead to vision loss.

“Quickly isolating and starting treatment can aid in stopping the spread of this novel coronavirus,” said corresponding author Deepesh Khanna from the varsity’s Department of Foundational Sciences.

The study, based on a review of 233 research papers from 2020 to 2024, also revealed that some patients may present with ocular symptoms as the first indication of Covid-19 infection.

This is because ACE2 receptors that are present in the eye act as entrypoint for SARS-CoV-2 virus to infect cells and cause Covid, the team explained. The ACE2 receptors present in eyes also “allow for easy transmission of the virus into the conjunctiva”.

“As the number of Covid-19 cases with ophthalmic infection continues to rise, further research must be conducted into the specific pathophysiology of ocular manifestations. Physicians should be informed on how to treat these symptoms, should they come into contact with those patients presenting with ophthalmic manifestations of Covid-19,” the researchers wrote in the paper.

While there is no current cure for Covid, the study showed that Pfizer’s Paxlovid (nirmatrelvir/ritonavir) medication, “may help treat Covid-19-positive patients with ophthalmic symptoms”.

The medication was approved by the US FDA in December 2021 for patients with mild to moderate Covid who are at risk of worse outcomes. The medication can halt viral replication and reduce viral load in the body.

–IANS

rvt/svn

Go to Source

Disclaimer

The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.

Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.

Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

For any legal details or query please visit original source link given with news or click on Go to Source.

Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.

If you are not willing to accept this disclaimer then we recommend reading news post in its original language.

MGID